Ragweed allergy vaccine sublingual tablet - ALK-Abello/Merck

Drug Profile

Ragweed allergy vaccine sublingual tablet - ALK-Abello/Merck

Alternative Names: ALK Ragweed Tablet; MK-3641; Ragweed AIT; Ragweed allergy immunotherapy - ALK-Abello; Ragweed extract - ALK-Abello; Ragwitek; SCH 039641; SCH 39641; SLITone ULTRA 302 Ragweed Anfangsbeh; SLIToneULTRA Ragweed

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ALK-Abello
  • Developer ALK-Abello; Merck & Co
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Seasonal allergic rhinitis

Most Recent Events

  • 31 Jan 2017 Merck terminates its licence for ragweed allergy vaccine in North America (ALK-Abello Annual Report 2016; 9212363)
  • 26 Jul 2016 Merck intends to terminate its licence for Ragweed allergy vaccine tablet in North America by early 2017
  • 01 Jul 2015 Phase-III clinical trials in Seasonal allergic rhinitis (In adolescents, In children) in USA (Sublingual) (NCT02478398)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top